New Antibody-Drug combo targets Hard-to-Treat digestive cancers

NCT ID NCT05628857

Completed Disease control Sponsor: RemeGen Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a drug called RC108 in 29 people with advanced digestive system cancers that have a protein called c-Met. RC108 is an antibody-drug combination given through a vein. The study looked at how well the drug shrinks tumors and what side effects occur. Results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RC108 (an antibody-drug combination given by IV)
What this could lead to: If successful, RC108 could offer a new treatment option for people with advanced digestive cancers that have a specific marker (c-Met).
What could go wrong: This is a small, early-phase trial with only 29 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIGESTIVE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIGESTIVE CANCER

Contacts and locations

Locations

Beijing Cancer Hopspital

Beijing, Beijing Municipality, 000000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.